Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
CN |
|
Duni AB
STO:DUNI
|
SE |
|
I
|
IDJ Vietnam Investment JSC
VN:IDJ
|
VN |
|
G
|
Gigante Salmon AS
OSE:GIGA
|
NO |
|
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
US |
|
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
|
US |
|
Canacol Energy Ltd
TSX:CNE
|
CA |
|
TPG RE Finance Trust Inc
NYSE:TRTX
|
US |
|
D
|
Dk&D Co Ltd
KOSDAQ:263020
|
KR |
|
Atlantic American Corp
NASDAQ:AAME
|
US |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Tibet Rhodiola Pharmaceutical Holding Co's stock price target?
Not Available
Tibet Rhodiola Pharmaceutical Holding Co doesn't have any price targets made by Wall Street professionals.
What is Tibet Rhodiola Pharmaceutical Holding Co's Revenue forecast?
Projected CAGR
9%
For the last 14 years the
compound annual growth rate for
Tibet Rhodiola Pharmaceutical Holding Co's revenue is
8%.
The projected
CAGR
for the next 3 years is
9%.
What is Tibet Rhodiola Pharmaceutical Holding Co's Operating Income forecast?
Projected CAGR
-16%
For the last 14 years the
compound annual growth rate for
Tibet Rhodiola Pharmaceutical Holding Co's operating income is
39%.
The projected
CAGR
for the next 8 years is
-16%.
What is Tibet Rhodiola Pharmaceutical Holding Co's Net Income forecast?
Projected CAGR
6%
For the last 14 years the
compound annual growth rate for
Tibet Rhodiola Pharmaceutical Holding Co's net income is
31%.
The projected
CAGR
for the next 3 years is
6%.
